Background Evidence from retrospective studies suggests that disease progression after first-line
chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …

PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …

Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT)
induce greater pathologic response rates than CT alone in patients with operable non-small …

Background A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early-…

Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with resected
stage II or III non–small-cell lung cancer. However, biomarker-informed clinical trials are …

Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the
treatment of many solid tumors. However, the clinical efficacy of immune checkpoint therapy is …

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – …

BACKGROUND: Endoscopic resection and ablation have advanced the treatment of
intramucosal esophageal adenocarcinoma and have been promoted as definitive therapy for …

8504 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major
pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of …